New research in an animal model suggests that a diet high in inorganic phosphates, which are found in a variety of processed foods including meats, cheeses, beverages, and bakery products, might speed growth of lung cancer tumors and may even contribute to the development of those tumors in individuals predisposed to the disease.
Ads by Google
Scientists at the University of Liverpool will undertake a study to assess the feasibility of undertaking a UK-based screening trial for lung cancer. The study has been commissioned by the National institute for Health Research Health Technology Assessment (NIHR HTA) programme.
Lung cancer kills more people worldwide than any other malignancy accounting for around 1.4 million deaths each year, and around 38,000 individuals are diagnosed with the disease in the UK each year.
The New Hampshire Department of Health and Human Services (DHHS) Tobacco Prevention and Control Program (TPCP) is challenging all smokers who want to quit to try again.
Lung cancer kills more than four times as many Americans as breast cancer. But while pink ribbons trumpet Breast Cancer Awareness Month throughout October, little attention is paid to lung cancer in November, which is that disease’s awareness month.
“My wish is the world would stand up and say we’ve done so well with breast cancer, let’s now do the same for lung cancer,” says Douglas Arenberg, M.D., associate professor of internal medicine and a lung cancer specialist at the University of Michigan Comprehensive Cancer Center.
Public smoking laws are frequently ignored. Most recently, India initiated a smoking ban, but many experts wondered if it would work. A major impetus to save lives through smoking cessation will save millions of lives worldwide. The Great American Smokeout 2008 is the latest effort to curb a genuine global health issue of smoking. Today is a focus of much attention to encourage Americans to stop smoking.
November marks National Lung Cancer Awareness Month and the Michigan Department of Community Health (MDCH) is proud to participate in the national effort to raise public attention about this disease.
Genetech Inc and OSI Pharmaceuticals have announced their drug Tarceva is effective in delaying the advance of lung cancer. Tarceva is a target agent that is currently used as a second line treatment for patients with Non-small cell lung cancer (NSCLC) after they have failed chemotherapy. OSI and Genentec said their drug met its main goal in a primary treatment clinical trial as it stopped the spread of advanced NSCLC significantly longer than placebo.
A multi-institution team, funded by the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH), today reported results of the largest effort to date to chart the genetic changes involved in the most common form of lung cancer, lung adenocarcinoma. The findings should help pave the way for more individualized approaches for detecting and treating the nation's leading cause of cancer deaths.
Patients operated on by surgeons who do not routinely remove cancer from the lungs may be at a higher risk for complications, according to a study conducted by researchers at Duke University Medical Center.
"Our study found that hospitals that do higher volumes of these types of surgeries have correspondingly lower mortality rates than those who do fewer of the procedures," said Andrew Shaw, M.D., an anesthesiologist at Duke and lead investigator on the study.
Lung cancer is one of the most common — and deadliest — cancers. Small cell lung cancer makes up about 10 percent to 15 percent of all lung cancers. Because of early metastatic spread, small cell lung cancer has very poor long-term survival with less than 10 percent of patients surviving two years after diagnosis.
Chemotherapy is the most common treatment for small cell lung cancer and many consider drugs containing platinum the most effective agents. However, a new evidence review calls that assumption into question.